A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases.  The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly and quarterly administration as target […]